Results 231 to 240 of about 127,720 (302)

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

open access: yesEpilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang   +3 more
wiley   +1 more source

LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma. [PDF]

open access: yesJ Immunother Cancer
Hou X   +15 more
europepmc   +1 more source

Frequency of anti‐neural antibodies and autoimmune epilepsy in focal epilepsy of unknown etiology: An observational study in a Singaporean cohort

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Autoimmune epilepsy (AES) is increasingly recognized as a condition in patients with epilepsy of unknown etiology. Early immunotherapy improves outcomes; however, data on its prevalence and the frequency of anti‐neural/neuronal antibodies in Asian populations remain scarce.
Seong Jin Park   +14 more
wiley   +1 more source

Investigation of Epstein-Barr virus or human cytomegalovirus in pediatric gliomas: A retrospective single-center study from Tunisia. [PDF]

open access: yesBiochem Biophys Rep
Missaoui N   +10 more
europepmc   +1 more source

Engineering mRNA‐LNP Medicines for the Ageing Brain: Opportunities and Challenges for Neurodegenerative Diseases

open access: yesExploration, EarlyView.
This review highlights recent advances in engineering messenger RNA (mRNA)‐lipid nanoparticles (LNPs) to cross the ageing blood–brain barrier and target neurodegenerative diseases. It outlines design principles, delivery routes, and translational challenges, charting a roadmap towards clinical application of mRNA‐LNP therapeutics for neurodegenerative ...
Abdel Ali Belaidi   +5 more
wiley   +1 more source

Illuminating point‐of‐care diagnostics with aggregation‐induced emission biosensors

open access: yesFlexMat, EarlyView.
This review highlights the application of aggregation‐induced emission luminogens (AIEgens) in point‐of‐care (POC) diagnostics for disease biomarker detection. It systematically examines a range of biosensing platforms, including lateral flow immunoassays, microfluidic chips, and electrochemiluminescence sensors, alongside their utility in detecting ...
Danni Hu   +3 more
wiley   +1 more source

Longitudinal Swallowing and Salivary Changes With CLR 131 and Re‐Irradiation in Recurrent Head and Neck Cancer

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Patients with recurrent head and neck cancer (HNC) often present with severe, persistent dysphagia and xerostomia following prior chemoradiation. Although swallowing impairments and salivary dysfunction have been reported in this population, prior longitudinal studies have not examined changes in salivary composition or how these ...
Jenni Wu   +8 more
wiley   +1 more source

Label-free two-photon fluorescence lifetime imaging of FADH<sub>2</sub> for rapid diagnosis and grading of glioma. [PDF]

open access: yesJ Biomed Opt
Wang S   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy